| Year |
Citation |
Score |
| 2024 |
Hossain MM, King P, Hackett J, Gerard HC, Niwinski R, Wu L, Van Kaer L, Dyson G, Gibson H, Borowsky AD, Sebzda E. Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner. Proceedings of the National Academy of Sciences of the United States of America. 121: e2404916121. PMID 39207730 DOI: 10.1073/pnas.2404916121 |
0.404 |
|
| 2024 |
Denison M, Ullrich A, Herroon MK, Mecca S, Turro C, Podgorski I, Gibson H, Kodanko JJ. Ru(II)-Photoactive Agents for Targeting ER Stress and Immunogenic Cell Death. Biorxiv : the Preprint Server For Biology. PMID 39091867 DOI: 10.1101/2024.07.18.604104 |
0.416 |
|
| 2023 |
Hackett JB, Ramos N, Barr S, Bross M, Viola NT, Gibson HM. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors. Frontiers in Oncology. 13: 1285117. PMID 38130991 DOI: 10.3389/fonc.2023.1285117 |
0.35 |
|
| 2022 |
Wallace-Povirk A, Rubinsak L, Malysa A, Dzinic SH, Ravindra M, Schneider M, Glassbrook J, O'Connor C, Hou Z, Kim S, Back J, Polin L, Morris RT, Gangjee A, Gibson H, et al. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. Scientific Reports. 12: 11346. PMID 35790779 DOI: 10.1038/s41598-022-14788-5 |
0.318 |
|
| 2022 |
Viola NT, Glassbrook JE, Kalluri JR, Hackett JB, Wicker MN, Sternberg J, Gibson HM. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Frontiers in Immunology. 13: 870110. PMID 35634303 DOI: 10.3389/fimmu.2022.870110 |
0.309 |
|
| 2020 |
Wei WZ, Gibson HM, Jacob JB, Frelinger JA, Berzofsky JA, Maeng H, Dyson G, Reyes JD, Pilon-Thomas S, Ratner S, Wei KC. Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. Journal of Immunology (Baltimore, Md. : 1950). PMID 32796024 DOI: 10.4049/Jimmunol.2000466 |
0.588 |
|
| 2020 |
McCarthy CE, White JM, Viola NT, Gibson HM. Imaging Technologies to Monitor the Immune System. Frontiers in Immunology. 11: 1067. PMID 32582173 DOI: 10.3389/Fimmu.2020.01067 |
0.356 |
|
| 2020 |
White JM, Keinänen OM, Cook BE, Zeglis BM, Gibson HM, Viola NT. Removal of Fc Glycans from [Zr]Zr-DFO-anti-CD8 prevents peripheral depletion of CD8 T cells. Molecular Pharmaceutics. PMID 32330387 DOI: 10.1021/Acs.Molpharmaceut.0C00270 |
0.417 |
|
| 2019 |
Jones RF, Reyes JD, Gibson HM, Jacob JB, Vaishampayan U, Ratner S, Chen K, Wei WZ. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice. Cancer Immunology, Immunotherapy : Cii. PMID 31177328 DOI: 10.1007/S00262-019-02333-9 |
0.62 |
|
| 2019 |
Gibson HM, Viola NT. The importance of examining an active immune system during immunotherapy. Oncotarget. 10: 559-560. PMID 30728906 DOI: 10.18632/Oncotarget.26580 |
0.405 |
|
| 2018 |
Gibson HM, McKnight BN, Malysa A, Dyson G, Wiesend W, McCarthy CE, Reyes J, Wei WZ, Viola-Villegas NT. Interferon-gamma PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy. Cancer Research. PMID 30115693 DOI: 10.1158/0008-5472.Can-18-0253 |
0.611 |
|
| 2016 |
Gibson H, Jones RF, Reyes JD, Wei W. Abstract 2361: Novel animal models for prediction of cancer vaccine response Cancer Research. 76: 2361-2361. DOI: 10.1158/1538-7445.Am2016-2361 |
0.625 |
|
| 2015 |
Wei WZ, Jones RF, Juhasz C, Gibson H, Veenstra J. Evolution of animal models in cancer vaccine development. Vaccine. 33: 7401-7. PMID 26241945 DOI: 10.1016/J.Vaccine.2015.07.075 |
0.664 |
|
| 2015 |
Veenstra JJ, Gibson HM, Freytag S, Littrup PJ, Wei WZ. In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence. Oncoimmunology. 4: e989762. PMID 25949901 DOI: 10.4161/2162402X.2014.989762 |
0.61 |
|
| 2015 |
Gibson H, Munns S, Freytag S, Barton K, Veenstra J, Bettahi I, Bissonette J, Wei WZ. Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncoimmunology. 4: e984523. PMID 25949865 DOI: 10.4161/2162402X.2014.984523 |
0.629 |
|
| 2015 |
Wong HK, Gibson H, Hake T, Geyer S, Frederickson J, Marcucci G, Caligiuri MA, Porcu P, Mishra A. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. The Journal of Investigative Dermatology. 135: 2084-92. PMID 25806852 DOI: 10.1038/Jid.2015.116 |
0.343 |
|
| 2015 |
Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ. Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunology Research. 3: 777-86. PMID 25711535 DOI: 10.1158/2326-6066.Cir-14-0175 |
0.617 |
|
| 2014 |
Zou Y, Xie L, Carroll S, Muniz M, Gibson H, Wei WZ, Liu H, Mao G. Layer-by-layer films with bioreducible and nonbioreducible polycations for sequential DNA release. Biomacromolecules. 15: 3965-75. PMID 25360688 DOI: 10.1021/Bm5010433 |
0.473 |
|
| 2014 |
Veenstra JJ, Gibson HM, Littrup PJ, Reyes JD, Cher ML, Takashima A, Wei WZ. Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. Cancer Research. 74: 5409-20. PMID 25092895 DOI: 10.1158/0008-5472.Can-14-0501 |
0.626 |
|
| 2014 |
Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, Wong HK. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes and Immunity. 15: 25-32. PMID 24173147 DOI: 10.1038/Gene.2013.57 |
0.336 |
|
| 2013 |
Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome. The Journal of Investigative Dermatology. 133: 249-57. PMID 22951729 DOI: 10.1038/Jid.2012.265 |
0.364 |
|
| 2013 |
Gibson HM, Jones R, Piechocki M, Reyes J, Sauerbrey M, Vaishampayan U, Wei W. Abstract 470: Electrovaccination of domestic cats with a hybrid heterologous Her2 DNA vaccine overcomes immune tolerance to self Her2. Cancer Research. 73: 470-470. DOI: 10.1158/1538-7445.Am2013-470 |
0.653 |
|
| 2013 |
Mishra A, Sullivan L, Sams G, Johns J, Curphey D, Falkenberg L, Gibson H, Liu S, Jaroncyk L, McConnell K, Wong H, Perle KL, Garzon R, Marcucci G, Porcu P, et al. Abstract 3857: Targeting HDAC1 in a novel model of cutaneous T-cell lymphoma. Cancer Research. 73: 3857-3857. DOI: 10.1158/1538-7445.Am2013-3857 |
0.352 |
|
| 2012 |
Piechocki MP, Wu GS, Jones RF, Jacob JB, Gibson H, Ethier SP, Abrams J, Yagita H, Venuprasad K, Wei WZ. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. International Journal of Cancer. Journal International Du Cancer. 131: 2562-72. PMID 22419388 DOI: 10.1002/Ijc.27534 |
0.649 |
|
| 2011 |
Mishra A, Sams GH, Johns J, Curphey DP, Sullivan LA, Falkenberg LG, Gibson H, Liu S, Jaroncyk L, Carson W, Kulp SK, Chen C, Wong HK, Perle KL, Porcu P, et al. Abstract 2858: A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor Cancer Research. 71: 2858-2858. DOI: 10.1158/1538-7445.Am2011-2858 |
0.348 |
|
| 2007 |
Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, Wong HK. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. Journal of Immunology (Baltimore, Md. : 1950). 179: 3831-40. PMID 17785820 DOI: 10.4049/Jimmunol.179.6.3831 |
0.349 |
|
| 2006 |
Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock CJ, Berger CL, Edelson RL, Lim HW. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma. The Journal of Investigative Dermatology. 126: 212-9. PMID 16417239 DOI: 10.1038/Sj.Jid.5700029 |
0.364 |
|
| Show low-probability matches. |